Zacks Investment Research on MSN

Does Moderna's mRNA flu shot face a new challenge from GSK?

Moderna MRNA recently secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine. The decision is a significant milestone for the company, which gets an opportunity to establish a ...

6 Best Vaccine Stocks for 2026 and How to Invest

Learn about the companies that are manufacturing vaccines and what you should know before investing in vaccine stocks.
Nasdaq

Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation

Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation Positive booster data ...
WXYZ

Sanofi, GSK to seek US authorization for protein-based COVID-19 vaccine

LONDON (AP) — Drugmakers Sanofi and GlaxoSmithKline say they will seek regulatory approval for a new COVID-19 vaccine after human trials showed it provided a high level of protection against the ...
Reuters

GSK to develop plant-based COVID-19 vaccine with Canada's Medicago

(Reuters) - The world's largest vaccine-maker GSK has put its vaccine booster technology to work in a potential new COVID-19 shot, to be developed with a Canadian biopharmaceutical company backed by ...
RAPS

Recon: GSK, Sanofi in talks for £500M UK coronavirus vaccine deal; Regeneron begins Phase 2/3 trial for COVID-19 antibody cocktail

Recon: GSK, Sanofi in talks for £500M UK coronavirus vaccine deal; Regeneron begins Phase 2/3 trial for COVID-19 antibody cocktail Welcome to Regulatory Reconnaissance, your daily regulatory news and ...